The Neutrophil-to-Lymphocyte Ratio May be the Best Serological Biomarker in Predicting Longer Survival in Neoadjuvant Treatment of Triple-Negative Breast Cancer

Recently some serologic parameters emerged as potential prognostic factors of triple-negative breast cancer (TNBC). We aimed to establish the most relevant factors and select optimal cutoff points for prospective investigations. Data from 137 TNBC patients treated with neoadjuvant chemotherapy were analyzed. Beyond pathological factors, white blood cell, neutrophil (NE), lymphocyte (LY) and platelet counts, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII) were investigated at baseline and before the third cycle. In univariate analysis, most parameters at baseline (NE1, LY1, NLR1, PLR1, SII1), in multivariate analysis NLR1 and pathological stage showed significant association with survival.